Pulse Biosciences’ Nanosecond Pulsed Field Ablation (nsPFA™) Technology to be Featured in Several Presentations at The Heart Rhythm 2023 Annual Meeting
May 18 2023 - 7:00AM
Business Wire
Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its
novel and proprietary Nanosecond Pulsed Field Ablation (nsPFA)
technology for the treatment of atrial fibrillation, today
announced nsPFA will be featured in three presentations at the
upcoming Heart Rhythm 2023 Annual Meeting in New Orleans, LA from
May 19-21.
“We are very encouraged that the preclinical work completed with
our nsPFA devices will be featured among leading technologies at
the premier meeting of heart rhythm professionals from around the
world,” said Kevin Danahy, Chief Executive Officer of Pulse
Biosciences. “This data is a validation of the quality of the
preclinical work completed with our physician collaborators and our
opportunity to advance the treatment of atrial fibrillation. We are
excited to continue on the path towards first in-human clinical
use.”
Poster Presentations featuring nsPFA
Poster Session IV – Ablation May 21, 2023, at 9:30-11:30 am
CT
- Creating Deep Ventricular Lesions with Nanosecond Pulsed Field
Ablation: Pathological and Imaging Insights from Preclinical
Evaluation (Iwanari Kawamura MD, et al)
- Electron Microscopic Insights from An Acute Pulsed Field
Myocardial Lesion (Iwanari Kawamura MD, et al)
- Nanosecond Pulsed Field Ablation: Demonstration of Halo-Shaped
Lesions with a Novel Multielectrode System: Initial Preclinical
Experience (Jacob S Koruth MD, et al.)
About Pulse Biosciences®
Pulse Biosciences is a novel bioelectric medicine company
committed to health innovation that has the potential to improve
the quality of life for patients. The Company’s proprietary
Nanosecond Pulsed Field Ablation (nsPFA) technology delivers
nanosecond pulses of electrical energy to non-thermally clear cells
while sparing adjacent noncellular tissue. The Company is actively
pursuing the development of its nsPFA technology for use in the
treatment of atrial fibrillation as well as a select few other
opportunities currently served by alternative established ablation
procedures. Visit pulsebiosciences.com to learn more.
Pulse Biosciences, CellFX, Nano-Pulse Stimulation, NPS, nsPFA
and the stylized logos are among the trademarks and/or registered
trademarks of Pulse Biosciences, Inc. in the United States and
other countries.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230518005284/en/
Investor Contacts: Pulse Biosciences Kevin Danahy, CEO
510.241.1077 IR@pulsebiosciences.com
or Gilmartin Group Philip Trip Taylor 415.937.5406
philip@gilmartinir.com
Pulse Biosciences (NASDAQ:PLSE)
Historical Stock Chart
From Apr 2024 to May 2024
Pulse Biosciences (NASDAQ:PLSE)
Historical Stock Chart
From May 2023 to May 2024